Aerie Pharmaceuticals Receives Positive Feedback from FDA

-Rocket 2 Primary Endpoint Range Modified upon FDA Agreement- Conference Call and Webcast Today, June 15, at 5:00 p.m. ET

IRVINE, Calif. -- Aerie Pharmaceuticals, Inc. (AERI) (the “Company”), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today reported that the U.S. Food and Drug Administration (FDA) has agreed in written and verbal communications that Aerie may change the primary endpoint range of its second Phase 3 registration trial of Rhopressa^TM, named Rocket 2. With this agreement, the Company is changing the primary endpoint range to include patients with baseline intraocular pressures (IOPs) ranging from above 20 mmHg (millimeters of mercury) to below 25 mmHg. The former range for the primary endpoint of above 20 mmHg to below 27 mmHg will now represent a secondary endpoint range for Rocket 2.

BioLife Solutions CryoStor® Cited in New Journal Article on Results of Phase I/II Clinical Trial of Dendritic Cell Immunotherapy for Prostate Cancer

Clinical Grade CryoStor® Incorporated as Combined Freeze Media and Vehicle Solution for Administering Cells to Patients

BOTHELL, Wash., June 15, 2015 -- BioLife Solutions, Inc. (BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management app for smart shippers ("BioLife" or the "Company"), today announced that a new clinical article citing the use of the Company's CryoStor cryopreservation freeze media with a dendritic cell based vaccine was published in the journal Oncotarget. 

The article can be viewed here: Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.

RedHill Biopharma to Host Conference Call Today to Review Positive Phase III Top-Line Results With RHB-105 for H. Pylori Infection

TEL-AVIV, Israel, June 15, 2015  -- RedHill Biopharma Ltd. (RDHL) (RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced positive top-line results from its Phase III study with RHB-105 for the treatment of Helicobacter pylori (H. pylori) bacterial infection. Top-line results from the study demonstrated 89.4% efficacy in eradicating H. pylori infection with RHB-105.

The ERADICATE Hp first Phase III study successfully met its primary endpoint of superiority over historical standard of care efficacy levels of 70%, with high statistical significance (p <0.001). No serious adverse events, new or unexpected safety issues were identified in the study.